Compare TC & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TC | CNTX |
|---|---|---|
| Founded | 2010 | 2015 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.1M | 51.5M |
| IPO Year | 2018 | 2021 |
| Metric | TC | CNTX |
|---|---|---|
| Price | $1.72 | $0.63 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $6.60 |
| AVG Volume (30 Days) | 2.0M | ★ 4.4M |
| Earning Date | 03-28-2025 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 17.39 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.53 | $0.55 |
| 52 Week High | $19.99 | $3.62 |
| Indicator | TC | CNTX |
|---|---|---|
| Relative Strength Index (RSI) | 28.49 | 32.40 |
| Support Level | $1.49 | $0.55 |
| Resistance Level | $11.10 | $0.70 |
| Average True Range (ATR) | 0.52 | 0.06 |
| MACD | -0.00 | 0.06 |
| Stochastic Oscillator | 3.97 | 46.45 |
Token Cat Ltd has two reportable business segments: automotive electronics resale business and advertising business. The automotive electronics resale business focuses on sourcing, holding, and reselling automotive electronics products, and includes sales of automotive electronic component equipment and accessories, mainly consisting of communication device and power module. The Company procures products from third-party suppliers and resells them to customers through its sales channels. The advertising business currently consists mainly of proxy advertising services, through which the Company helps clients promote their brands, services and products on third-party online platforms. The automotive electronics resale business segment generates maximum revenue.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.